Future Directions and Unmet Needs in HER2+ Breast Cancer Therapy

EP: 1.Evolving Horizons in HER2-Positive Breast Cancer Care

EP: 2.Key HER2+ Patient Populations Evaluated in the DESTINY-Breast Program

EP: 3.Integrating Emerging DESTINY-Breast Data Into HER2+ Treatment Strategies

EP: 4.Interpreting Key Data From KATHERINE, HER2CLIMB-05, and PATINA

EP: 5.Defining Success in Metastatic Breast Cancer Trial Design

EP: 6.Personalized Selection of HER2+ Breast Cancer Therapies

EP: 7.Navigating ADC Use and Sequencing in HER2+ Breast Cancer

EP: 8.Balancing Efficacy and Safety in HER2+ Breast Cancer Trials

EP: 9.Exploring Off-Label HER2-Targeted Therapy in Early Breast Cancer

EP: 10.Optimizing Safety and Adherence in HER2-Targeted Therapy Through Nursing and AE Management

EP: 11.Addressing Care Coordination and Financial Toxicity in HER2+ Breast Cancer

Now Viewing

EP: 12.Future Directions and Unmet Needs in HER2+ Breast Cancer Therapy

As HER2-targeted therapies continue to evolve, clinicians and healthcare systems anticipate new indications that could expand treatment options across both early and metastatic settings. These advancements may influence formulary planning, requiring institutions to evaluate cost, access, and sequencing strategies to ensure timely adoption while maintaining sustainability. Despite progress, unmet needs remain significant. In early breast cancer, strategies are needed to improve outcomes for patients with residual disease and to minimize treatment-related toxicity. In the metastatic setting, challenges include overcoming resistance, optimizing therapy sequencing, and addressing complex patient subgroups such as those with HER2+/HR+ disease. Addressing these gaps will rely on continued clinical innovation, real-world evidence, and multidisciplinary collaboration, ultimately aiming to deliver more effective, personalized, and tolerable HER2-targeted treatment options across the continuum of care.